We are #2 because we put KIDS FIRST
This technology utilizes methods and compositions related to reducing the risk of or preventing fetal wastage by administering CXCR3 inhibitors.
IRAK1 is a drugable target for treatment of MDS, and IRAK1/BCL2 inhibitors synergistically co-treat MDS.
A Growing Pipeline of Innovations
Find out how we are building the research-to-market bridge in the latest Research Horizons
Partner with Us
View our innovation portfolio
May 23, 2019; 8:15am - Venture Capital Perspective: Tech-Enabled Investing
May 29, 2019; 8:15am - Learn from a Venture Capitalist: Make Your Pitch Stand Out
New TVSF Recipients
2019 TVSF Recipients